De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Coloplast Beheer

Beheer criteriumcontroles 4/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Kristian Villumsen

Algemeen directeur

DKK 21.4m

Totale compensatie

Percentage CEO-salaris	54.2%
Dienstverband CEO	4yrs
Eigendom CEO	0.04%
Management gemiddelde ambtstermijn	4.7yrs
Gemiddelde ambtstermijn bestuur	4.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Kristian Villumsen's beloning veranderd ten opzichte van Coloplast's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2022	DKK 21m	DKK 12m	DKK 5b
Jun 30 2022	n/a	n/a	DKK 5b
Mar 31 2022	n/a	n/a	DKK 5b
Dec 31 2021	n/a	n/a	DKK 5b
Sep 30 2021	DKK 22m	DKK 11m	DKK 5b
Jun 30 2021	n/a	n/a	DKK 5b
Mar 31 2021	n/a	n/a	DKK 4b
Dec 31 2020	n/a	n/a	DKK 4b
Sep 30 2020	DKK 20m	DKK 11m	DKK 4b
Jun 30 2020	n/a	n/a	DKK 4b
Mar 31 2020	n/a	n/a	DKK 4b
Dec 31 2019	n/a	n/a	DKK 4b
Sep 30 2019	DKK 17m	DKK 10m	DKK 4b
Jun 30 2019	n/a	n/a	DKK 4b
Mar 31 2019	n/a	n/a	DKK 4b
Dec 31 2018	n/a	n/a	DKK 4b
Sep 30 2018	DKK 11m	DKK 6m	DKK 4b
Jun 30 2018	n/a	n/a	DKK 4b
Mar 31 2018	n/a	n/a	DKK 4b
Dec 31 2017	n/a	n/a	DKK 4b
Sep 30 2017	DKK 10m	DKK 6m	DKK 4b
Jun 30 2017	n/a	n/a	DKK 3b
Mar 31 2017	n/a	n/a	DKK 3b
Dec 31 2016	n/a	n/a	DKK 3b
Sep 30 2016	DKK 10m	DKK 6m	DKK 3b

Compensatie versus markt: De totale vergoeding ($USD 3.06M ) Kristian } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de Swiss markt ($USD 4.82M ).

Compensatie versus inkomsten: De vergoeding van Kristian is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Kristian Villumsen (52 yo)

4yrs

Tenure

DKK 21,400,000

Compensatie

Mr. Kristian Villumsen has been Independent Director of Demant A/S since March 5, 2021. He has been the President and Chief Executive Officer of Coloplast A/S since December 4, 2018. Mr. Villumsen was an E...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Kristian Villumsen	President & CEO	4yrs	DKK 21.40m	0.043% CHF 10.5m
Anders Lonning-Skovgaard	Executive VP & CFO	8.4yrs	DKK 10.80m	geen gegevens
Allan Rasmussen	Executive Vice President of Global Operations	8.4yrs	DKK 9.60m	0.00015% CHF 36.8k
Nicolai Andersen	Executive Vice President of Innovation	no data	DKK 9.00m	geen gegevens
Paul Marcun	Executive Vice President of Growth	3.9yrs	DKK 11.00m	geen gegevens
Thomas Barfod	Senior Controller & Employees Representative Director	no data	DKK 450.00k	0.000030% CHF 7.4k
Ellen Bjurgert	Vice President of Investor Relations	6.2yrs	geen gegevens	geen gegevens
Dennis Kaysen	Director of Corporate Communications	no data	geen gegevens	geen gegevens
Dorthe Ronnau	Senior Vice President of People & Culture	less than a year	geen gegevens	geen gegevens
Alain Morvan	Senior Vice President of Sales Europe	10.7yrs	geen gegevens	geen gegevens
Rasmus Møller	Senior Vice President of Wound & Skin Care	2.3yrs	geen gegevens	geen gegevens
Manu Varma	Senior Vice President of Chronic Care - North America	4.7yrs	geen gegevens	geen gegevens

4.7yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 020259063 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.7 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Thomas Barfod	Senior Controller & Employees Representative Director	16.9yrs	DKK 450.00k	0.000030% CHF 7.4k
Carsten Hellmann	Independent Director	5yrs	DKK 690.00k	0.0028% CHF 694.2k
Lars Rasmussen	Chairman of the Board	4yrs	DKK 1.84m	0.098% CHF 24.0m
Niels Louis-Hansen	Deputy Chairman	54.9yrs	DKK 938.00k	21.14% CHF 5.2b
Marianne Wiinholt	Independent Director	2yrs	DKK 880.00k	0.00024% CHF 58.9k
Jette Nygaard-Andersen	Independent Director	7yrs	DKK 600.00k	geen gegevens
Nikolaj Gundersen	Employees Representative Director	4.9yrs	DKK 450.00k	0% CHF 0
Roland Pedersen	Employees Representative Director	4.9yrs	DKK 450.00k	0.00070% CHF 171.7k
Annette Bruls	Independent Director	less than a year	DKK 497.00k	geen gegevens

4.9yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 020259063 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Coloplast Beheer

Beheer criteriumcontroles 4/4

Belangrijke informatie

Recente managementupdates

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast Announces Executive Changes

Less than half of directors are independent

Less than half of directors are independent

Contraline Names Yelena Tropsha as CTO

Less than half of directors are independent

Recent updates

Coloplast A/S to Report First Half, 2025 Results on May 06, 2025

Coloplast A/S, Annual General Meeting, Dec 04, 2025

Coloplast A/S Re-Affirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/S Announces Interim Dividend for the First Half of 2023/24, Payable on May 15, 2024

Coloplast A/S Reaffirms Earnings Guidance for the Fiscal Year 2023/24

Coloplast A/SLaunches Biatain® Silicone Fit for Pressure Injury Prevention and Wound Management in the US

Coloplast A/S Approves the Distribution of Year-End Dividend

Coloplast A/S Provides Earnings Guidance for Fiscal Year 2023-2024

Coloplast A/S to Report Q1, 2024 Results on Feb 09, 2024

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S (CPSE:COLO B) completed the acquisition of Kerecis, LLC

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/2023

Coloplast A/S (CPSE:COLO B) signed an agreement to acquire Kerecis, LLC for $1.3 billion.

Coloplast A/S Provides Earnings Guidance for the Fiscal 2023

Coloplast Launches Male Catheter Designed to Reduce the Risk of Urinary Tract Infections

Coloplast A/S Provides Earnings Guidance for the Fiscal Year 2022/23

Coloplast Announces Executive Changes

Coloplast A/S Provides Financial Guidance for the Fiscal Year 2023

Coloplast Launches Saffron™ Fixation System for Prolapse Repair

Coloplast A/S to Report Fiscal Year 2023 Results on Nov 09, 2023

Coloplast A/S Provides Revenue Guidance for the Fiscal Year 2021-2022

Less than half of directors are independent

Less than half of directors are independent

Coloplast A/S Provides Earnings Guidance for the Full Year of 2022

Contraline Names Yelena Tropsha as CTO

Coloplast A/S (CPSE:COLO B) completed the acquisition of Atos Medical AB from PAI Europe VI, L.P., managed by PAI Partners.

First quarter 2022 earnings: Revenues exceed analyst expectations

Coloplast A/S Updates Earnings Guidance for the Year 2021/22

Independent Director Birgitte Nielsen has left the company

Upcoming dividend of kr.14.00 per share

Full year 2021 earnings released: EPS kr.22.67 (vs kr.19.74 in FY 2020)

Third quarter 2021 earnings released: EPS kr.5.89 (vs kr.4.69 in 3Q 2020)

Coloplast A/S Provides Earnings Guidance for the Year 2020/2021

Less than half of directors are independent

Coloplast A/S Provides Earnings for the Year 2021

Second quarter 2021 earnings released

First quarter 2021 earnings released

Revenue beats expectations

Coloplast A/S Elects Marianne Wiinholt as A New Member of the Board of Directors

Upcoming Dividend of kr.13.00 Per Share

Coloplast A/S (CPSE:COLO B) acquired Nine Continents Medical, Inc. for approximately $150 million.

Revenue misses expectations

Coloplast A/S to Report First Half, 2021 Results on May 06, 2021

Earnings released

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd